| Name | Title | Contact Details |
|---|
Bacterin is an accredited tissue bank and medical device company that designs, processes, manufactures, and markets advanced medical products. Using designs focused on efficacy and safety for the patient, and functionality and ease of use for the surgeon, our innovative products fulfill niche needs in the industry. It is important that you know and trust your allograft provider. We are a specialty tissue bank focused on processing and distributing quality, cost-effective allografts to you and your patients.
Doctor Diabetic Supply is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedicKey is a Ventura, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HemoSense is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.